Biomarkers play a very important role in identification, confirmation, treatment and prognosis of different oncological processes. Recently, a significant spike has been observed in the development and discovery of an increasing number of biomarkers that can help detect molecular characteristics of tumor cells in order to devise personalized treatment plans for cancer treatment.
Texas research institutes in particular are working toward the identification, detection and development of various biomarkers to improve the outcome of different cancers.
We reported in a previous article on BioNews Texas how Biomarkers may help predict the progression of Barrett’s esophagus to esophageal adenocarcinoma. Earlier this year, researchers from The University of Texas MD Anderson Cancer Center discovered the role of microRNA in the pathogenesis and progression of pre-cancerous conditions like Barrett’s esophagus into malignant esophageal adenocarcinoma. The report was published in Cancer Prevention Research that covered the details of research work by Head of Department of Epidemiology at The University of Texas MD Anderson Cancer Center, Xifeng Wu and her associates on the microRNA miR-375 down-regulation.
Development of cost-effective tools to test multiple biomarkers with one sample:
In addition, Myriad RBM utilized CPRIT funding to develop biomarker assays at Myriad RBM Multi-Analyte Profile (MAP) platform that enabled researchers to identify over 250 analytes with just one small sample. The outstanding tool – OncologyMAP® v2.0 – is a step towards the development of cost-effective strategies to increase the diversity and scope of analytical study on biomarkers.
The assay menu was utilized by L. Stephen in a survey for the detection of colorectal (CRC) and prostate (PC) tumors via detection of serum proteins as biomarkers. The results were published in the report entitled, “Analysis of Protein Biomarkers in Prostate and Colorectal Tumor Lysates.”
Read more about biomarkers at BioNews Texas
Stephen identified that the protein levels show alterations with changes in the tumor level. Essential features of the poster, including:
– 102 of 115 proteins from CRC and PC lysates presented levels above the lower limit of quantification.
– Along with similar results in many analytes, some tumor sections also showed significant changes (like difference of CEA in Tumor 4 and uPA in tumor 2).
– Almost 18 tumor markers show correspondence to serum tumor lbiomarkers.
Craig Bensen, the President of Myriad RBM, commented on the development of OncologyMAP® v2.0 in these words:
“Researchers have made great strides in understanding the relationship between protein biomarkers and cancer. Our goal has been to build on these isolated discoveries by creating a comprehensive and useful quantitative test that can be utilized to develop and validate new therapeutics. Using data provided by this service, researchers may shorten the time and cost of development while also improving the safety and efficacy of the compounds in their pipeline”
For continued reading, be sure to visit BioNews Texas’ news section on biomarkers.